II Editor
06 Jul 2016
NEW ARTICLE: 2016's best and worst investment funds " Gold funds have shone in the first half of 2016, with FUND:I008:Investec Global Gold leading the pack of our sister magazine Money Observer's Rated Funds, notching up an eye-catching return of 115%. The gold price has soared to a two-year high, ..."[link]
stressboy
26 Jan 2016
Re: Video interview Geoffrey Hsu, co-man... I still think 550 (to 570) could be the bottom (again looking on my phone is tricky to get the exact number)I am considering starting to build a position if/when this drops below 600....
PMP1
26 Jan 2016
Re: Video interview Geoffrey Hsu, co-manager Yes, and it's now at a low equal with 2014, how low will it go?
Kingel
26 Jan 2016
Video interview Geoffrey Hsu, co-manager The Biotech Growth Trust (BIOG ) has established one of the strongest long-term records of a UK-based fund, turning a £100 investment into £521 over 10 years as the biotechnology sector has ridden a wave of medical innovation and mergers and acquisitions (source: Morningstar Inc, Association of Investment Companies).In the past six months, however, the trust has experienced a serious setback with the shares down 18% since September as biotechnology companies have come under political pressure over drugs pricing and as a more cautious mood has swept global stock markets.In this video interview Geoffrey Hsu, co-manager of the £404 million trust, explains:[link]
Kingel
13 Nov 2015
Politicians wonÂ’t stop biotech boom A wave of blockbuster, life-saving drugs and bids will revive battered biotech stocks, says manager of Worldwide Healthcare trust.A wave of blockbuster, life-saving drugs and takeover bids will revive healthcare and biotech stocks and protect them from attack over high drug prices, says Sven Borho of Orbimed Advisors, a leading investor in the sector.Shares in drugs companies tumbled following a pledge to tackle pharmaceutical ‘price gouging’ made by Hilary Clinton, the former US foreign secretary seeking to lead the Democrat party in next year’s presidential election.US biotech shares plunged 20% and healthcare stocks by 10% in an eight-day period in September when the media furore over drug price hikes was at its height.Although share prices have since recovered some ground, concerns over the commercial practices of Valeant Pharmaceuticals have ensured the debate over healthcare costs has remained high up the US political agenda.Fact and fictionBorho, co-manager of the Worldwide Healthcare (WWH + ) investment trust, questioned if the issue had got too much attention. Speaking to investors in London yesterday Borho pointed to figures from the Centers for Medicare and Medicaid Services (CMS) that showed US spending on most prescription drugs rose by 2.7% a year on average in 2007-13, he asked: ‘Is 2.7% growth a massive problem?’While CMS forecasts showed prescription drug expenditure rising ahead of overall healthcare spending and growth in the US economy by 2023, the difference was small: 5.9% versus 5.7% growth in spending and 4.6% in GDP.‘What’s the reality? Are healthcare costs spiralling out of control?’ Borho asked.No changeHe also questioned whether Clinton – or her left-wing rival Bernie Saunders – could succeed in regulating drug prices. Clinton had tried and failed at reform in 1994 when her husband Bill was president and the Democrats had control over both parts of Congress, he said.In 2010, despite having Democrat majorities in both the House of Representatives and the Senate, president Obama had not pushed through price restrictions as part of his health care reforms.Borho said even if Clinton became president, she would probably face a Republican House and a divided Senate. A split Congress would not enact anything he said.‘The chances that everything will change if Hilary Clinton is elected are extremely remote,’ he said. New drugsNew York-based Orbimed is the world’s biggest specialist investor in healthcare with $15 billion under management. In the UK it is best known for the Worldwide Healthcare fund, which Borho runs with Sam Isaly, the firm’s managing partner, and the Biotechnology Growth (BIOG + ) investment trust, run by Geoff Hsu and Richard Klemm.Central to Orbimed’s confidence in healthcare prospects is what its team sees is the continuing trend for scientific innovation, drug development and corporate activity with companies with valuable assets bought by larger rivals.Although the drugs industry will remain vulnerable to criticism of over charging, ultimately the fund managers believe drugs companies will be able to levy high prices for successful treatments.Life saversOrbimed remains excited by developments in immuno-oncology where a new generation of drugs teaches the body to fight the cells responsible for a wide range of cancers.Borho gave the example of Opdivo, a treatment for advanced melanoma, or skin cancer, developed by Bristol-Myers Squibb of the US and Ono Pharmaceuticals of Japan.Approved for sale in the past year in Japan and the US, Opdivo was fast-tracked in the UK this summer for use against lung cancer. It was evident in Bristol-Myers’ recent third quarter results, helping the world’s 15th biggest drugs company by revenue beat analysts’ earnings forecasts.That’s because Opdivo is expensive. According to the company, the first year of treatment using the drug in combination with others is around $256,0
valeite
10 Nov 2015
Re: 550 support? and do the reverse when selling......a slice at a time .
rugosaplants
10 Nov 2015
Re: 550 support? The wise thing to do is buy in small chunks each month. If the price continues to increase, you will feel comfortable, but if it drops away, you will not feel you are losing much. I have employed this thinking in the past and life is much more relaxed as a result.
stressboy
09 Nov 2015
Re: 550 support? Yep, you're 'just north of 600p' support was bang on.SO.Is this the start of the return to an uptrend? Or will we see a lower high and the drift continue with a lower low to come...Mulling it over......
Einstein the Second
04 Nov 2015
Re: 550 support? Looks like it has put in a bottom for now, should see 8 quid at least I reckon.
vic1981
29 Oct 2015
Re: Time to buy? believe so too. We have a firm bottom I guess.
Richygm
28 Oct 2015
Time to buy? Views anyone?
lambrini girl
07 Oct 2015
Re: 550 support? Out of interest how do you see the markets as a whole behaving over the next few months? <<<<volatile/sideways..certainly dont get carried away by bullish tones at moment..markets wont take off for at least 3 years yet..(Andy Reilly doesnt offer anything of value)
stressboy
07 Oct 2015
Re: 550 support? Thanks Lambrini girl, not that these supports always work! I noticed around 290-300 for BRWM (currently 220ish)I have noticed you on the odd board (AMC and ACTA I think) and I have noticed you do at time get the odd bit of stick (AMC and ACTA I think). To be honest I¡¦ve never really taken the time to see what the comments are about but we are clearly in agreement here and I might have to start to read more of your posts ƒº. I know you are a mug to follow other posters but I do tend to read Andy Reilly on AMC as I feel his posts tend to accurately reflect the market sentiment on whatever he is posting about.Out of interest how do you see the markets as a whole behaving over the next few months? I¡¦m really quite jittery about a major correction being on the way for the markets as a whole..
lambrini girl
06 Oct 2015
Re: 550 support? Looking on the 5 year chart there is support at 550 <<well spotted stressie....I pointed this out a Year ago (I got lots o stick!)...
lambrini girl
06 Oct 2015
Re: Some recovery SELL target 550..<<<gonna give meself a BANG ON!!..recent drop near enuff...will go lower..I warned previous Pharma/Bio rolling over..
